Contribution of H-Bonding to the Preference of Platinum Anti-tumour Drugs for Particular Bases and Particular Cross-Links
1994
How Platinum Anti-Cancer Drugs Prefer Certain DNA Bases
publication
Evidence: moderate
Author Information
Author(s): Giovanni Natile
Primary Institution: Dipartimento Farmaco-Chimico, Bari, Italy
Hypothesis
The study investigates how hydrogen bonding influences the binding preferences of platinum anti-cancer drugs to specific DNA bases.
Conclusion
The study concludes that varying the stereochemistry of the N-H bonds and the hydrogen bonding ability of ligands can determine the binding preferences of platinum complexes to DNA.
Supporting Evidence
- Platinum compounds preferentially bind to guanine in DNA.
- Hydrogen bonding plays a significant role in the binding specificity of platinum drugs.
- Different isomers of platinum complexes show varying levels of antitumor activity.
Takeaway
This study looks at how certain cancer drugs made from platinum like to stick to specific parts of DNA, which helps them fight cancer better.
Methodology
The study examines the stereochemical factors influencing the binding of platinum drugs to DNA and models the interactions.
Want to read the original?
Access the complete publication on the publisher's website